20 studies found for:    "Noonan syndrome 5"
Show Display Options
RSS Create an RSS feed from your search for:
"Noonan syndrome 5"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)
Condition: Hepatitis C, Chronic
Interventions: Drug: IDX719;   Drug: Placebo
2 Recruiting An Observational/Non-interventional, Study of NS3/4a Protease and NS5A Protein of Hepatitis C Virus in Brazilian Participants With Chronic HCV Infection
Condition: Hepatitis C Virus
Intervention:
3 Active, not recruiting A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4
Condition: Chronic Hepatitis C
Interventions: Drug: ravidasvir hydrochloride;   Drug: sofosbuvir;   Drug: ribavirin
4 Active, not recruiting Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF/VEL/VOX;   Drug: SOF/VEL
5 Completed Ph IIA Study (SOC +/- NS5B)
Condition: Hepatitis C Virus
Interventions: Drug: BMS-791325;   Drug: Placebo;   Drug: Peg-interferon alfa-2a;   Drug: Ribavirin
6 Completed TD-6450 SAD and MAD in Healthy Subjects
Condition: Hepatitis C
Interventions: Drug: TD-6450;   Drug: Placebo
7 Completed TD-6450 MAD Study in HCV Infected Subjects
Conditions: Hepatitis C;   HCV
Interventions: Drug: TD-6450;   Drug: Placebo
8 Completed Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: PPI-668;   Drug: BI 207127 Dose 1;   Drug: BI 207127 Dose 2;   Drug: Faldaprevir;   Drug: Ribavirin;   Drug: BI 207127 Placebo
9 Completed Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C.
Condition: Hepatitis C, Chronic
Interventions: Drug: GSK2878175;   Drug: Placebo
10 Completed A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single & Repeat Escalating Doses of GSK2878175 in Healthy Subjects
Condition: Hepatitis C, Chronic
Interventions: Drug: GSK2878175;   Drug: Placebo
11 Completed A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1
Condition: Chronic Genotype 1 Hepatitis C Virus Infection
Interventions: Drug: PPI-461;   Drug: Placebo
12 Completed A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
Condition: HCV Infection
Interventions: Drug: GS-5885;   Drug: Placebo
13 Completed Dose Ranging of GSK2336805 in Combination Therapy
Condition: Hepatitis C, Chronic
Interventions: Drug: GSK2336805 40 mg;   Drug: GSK2336805 60 mg;   Drug: Pegylated interferon alpha-2a;   Drug: Ribavirin;   Drug: Telaprevir
14 Completed A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1
Condition: Hepatitis C, Chronic
Interventions: Drug: PPI-668;   Drug: Placebo
15 Completed Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects
Condition: Hepatitis C, Chronic
Interventions: Drug: GSK2336805;   Drug: Pegylated interferon alfa-2a;   Drug: Ribavirin;   Drug: GSK2336805 Matching Placebo
16 Completed
Has Results
Safety, Tolerability and Efficacy of 12-weeks of Sovaprevir, ACH-3102 and Ribavirin in Treatment-naive GT-1 HCV Subjects
Condition: Hepatitis C, Chronic
Interventions: Drug: Sovaprevir;   Drug: ACH-3102;   Drug: RBV;   Drug: Placebo
17 Completed A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients
Condition: Hepatitis C, Chronic
Interventions: Drug: PPI-383;   Drug: Placebo
18 Terminated GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype
Condition: Chronic Hepatitis C
Interventions: Drug: GS-5885;   Drug: GS-9451;   Drug: RBV;   Drug: PEG
19 Terminated Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382
Condition: Chronic Hepatitis C Infection
Interventions: Drug: Placebo;   Drug: JNJ-47910382
20 Unknown  A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients
Condition: Chronic Hepatitis C Infection
Interventions: Drug: JNJ-47910382 30 mg;   Drug: JNJ-47910382 90 mg;   Drug: JNJ-47910382 200 mg;   Drug: Placebo

Indicates status has not been verified in more than two years